Clinical trials
PDAC clinical trials
Below are recruiting pdac clinical trials, each written for real people, not researchers. We’re tracking 103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04575363Recruiting
Testing a blood marker to predict pancreatic cancer outcomes
This study looks at a test called RPSA to see if it can help predict how pancreatic cancer may turn out. It includes people being treated at Reims University Hospital for pancreatic tumors that can be removed (or may become removable).
ReimsAges 18 years+ - NCT06145074RecruitingPhase 2
Testing propranolol before surgery for pancreatic cancer
This trial tests if taking propranolol (a blood pressure medication) before surgery helps treat pancreatic cancer that can be removed. It aims to see if the drug is safe and works well.
CopenhagenAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT06261359RecruitingPhase 2
CEND-1 plus chemo for first-line pancreatic cancer
This trial tests a new drug called CEND-1 combined with standard chemotherapy for people with advanced pancreatic cancer that has not been treated before. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT07723261Recruiting
Testing NalIriFOx as first treatment for metastatic pancreatic cancer
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
AthensAges 18 years+ - NCT07714538Recruiting
Breath test for detecting gastrointestinal cancers
This study tests whether a simple breath test can help detect different types of gastrointestinal cancers earlier. If you have been recently diagnosed with one of these cancers or have concerning abdominal symptoms but clear test results, your breath may help teach us how to spot these cancers sooner.
Maidstone, KentAges 18 years+ - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT07683845Recruiting
Using a tumor model to predict chemo response in pancreatic cancer
This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07678593RecruitingPhase 1/Phase 2
Study of a new drug combined with standard therapy for RAS-mutated cancers
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
Concord, New South WalesAges 18 years+ - NCT07659639Recruiting
A blood test using light to find pancreatic cancer early
This trial tests a new blood test that uses tiny particles and a laser to find signs of pancreatic cancer earlier. It may help people with pancreatic ductal adenocarcinoma (PDAC) or intraductal papillary mucinous neoplasms (IPMN), a type of cyst that can become cancer.
Rome, ItalyAges 18 years+ - NCT07644559RecruitingPhase 2
Study of VS-7375 with cetuximab for advanced pancreatic cancer
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07640295RecruitingPhase 1/Phase 2
New drug plus chemo for advanced pancreatic cancer with KRAS mutation
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75 - NCT07587866Recruiting
Panuri Test for Suspected Pancreatic Cancer
This study tests a new diagnostic tool called Panuri to help detect pancreatic cancer in adults who have symptoms suggesting the disease. The test may help doctors identify pancreatic cancer earlier and more accurately.
BékéscsabaAges 18 years+ - NCT07554560Recruiting
Nutrition Support for Pancreatic Cancer Patients
This study tests a nutrition intervention for people with pancreatic cancer who are having trouble eating or absorbing nutrients. The goal is to help patients maintain strength and improve their quality of life during cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06405490RecruitingPhase 2
Chemo plus immunotherapy for first-line advanced pancreatic cancer
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07542041Recruiting
Pancreatic Cancer Detection Using Advanced Tissue Analysis
This study tests a new way to analyze tiny samples of pancreatic tissue taken during a biopsy to better detect cancer. The method uses special technology to examine the physical properties of cells, which may help doctors diagnose pancreatic cancer more accurately.
Tampa, FloridaAges 18 years+ - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT07490301RecruitingPhase 2/Phase 3
Study of a new drug combo for first-line metastatic pancreatic cancer
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
New Haven, ConnecticutAges 18 years+ - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+
Hear when a new PDAC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pdac?
- Yes. Clin2 currently lists 103 recruiting pdac studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pdac trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pdac trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.